1/ “Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.” $PVCT thoughts: there’s no free lunch. A THREAD.
2/ 20Mar23: Endpoints: “BioNTech to pay $200M upfront in CTLA-4 antibody development, commercialization deal.” endpts.com/biontech-to-pa….
1/ The impact of #Covid on $PVCT’s R&D, #DrugDiscovery, and clinical development of our #HalogenatedXanthene (#HX) medical science platform and #RoseBengalSodium (#RBS) investigational drug & drug formulation pipeline. A #THREAD.
2/ This $PVCT #thread will be an ongoing one for some time. Please check back to read it again (and again), and learn more about our medical scientific history and our lead molecule #RoseBengalSodium’s journey to becoming a multi-disease, broad-spectrum, therapeutic compound.
$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA produces antigens from a defined library; PV-10 produces antigens present in an injected tumor that may extend beyond what's contained in the library
$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA presumably is based on genomic profiling of a single tumor; PV-10 produces antigens specific to each injected tumor